Post-Funding Strategy for Life Sciences Startups
Updated: Sep 7
Raising a round is a milestone, not a market position. The capital buys time to build commercial proof, and the next round will be priced on whether you built it.
This guide sets out what a life sciences company should put in place in the first two quarters after a financing, and what the current funding data says about how much commercial evidence investors now expect.
What the 2025 funding data actually shows
Global venture funding reached 425 billion dollars across more than 24,000 companies in 2025, up 30 percent from 328 billion dollars in 2024, according to Crunchbase. Healthcare and biotech was the second largest sector, at roughly 71.7 billion dollars.
That headline is encouraging and slightly misleading. Aggregate totals hide where the money lands.
HSBC Innovation Banking reported biotech venture funding of 7 billion dollars in the first quarter of 2025 and 4.8 billion dollars in the second, tied for the worst quarterly total in three years, as reported by BioPharma Dive. First financings fell from 2.6 billion dollars to 900 million dollars over those two quarters, the lowest total in five quarters. Rounds of 100 million dollars or more dropped from 21 to 16.
Read together, the two datasets say the same thing. Capital is available and it is concentrating in later, de-risked rounds. For a company that has just closed a Series A or B, the practical consequence is direct: the next raise will be judged on commercial evidence, not only on scientific progress.
Why funded life sciences companies stall commercially
Funding removes the immediate constraint and exposes the next one. Three patterns show up repeatedly in companies that raise well and then lose momentum.
Commercial strategy starts after the product. The go-to-market plan waits for a launch date, which means the first real customer conversation happens twelve to eighteen months later than it needed to.
Hiring runs on urgency rather than fit. A senior commercial hire is made because the board expects one, before anyone has defined which segment the company sells to or what a qualified opportunity looks like.
Cycle length is underestimated. Teams plan on quarterly sales rhythms in a market where a single decision can take a year, then read the silence as a product problem.
1. Build the commercial strategy in parallel with R&D
A business development roadmap should sit alongside your development milestones, not behind them. Every technical milestone is also a commercial event: a proof of concept gives you a first reference conversation, a completed batch gives you a capability claim, a regulatory filing gives you a reason to reopen a dormant contact.
Practically, that means three things are defined before launch: the market segments worth pursuing, the positioning that connects your scientific value to a buyer problem, and the two or three channels you will actually use. A plan that lists eight channels is a plan nobody runs.
2. Define the buyer before you hire the seller
The most expensive post-funding mistake is hiring a commercial leader to figure out the market. That is the founder's job first. A senior hire executes a defined go-to-market, they rarely invent one from scratch inside a company that has not decided who it serves.
Before a commercial hire, write down the segment, the titles that sign, the titles that block, the trigger events that create a window, and what disqualifies an account. If that document does not exist, a new hire spends their first two quarters producing it, at senior salary, while the pipeline stays empty.
The roles that matter early are usually key account managers, business developers and regional directors, onboarded into a strategy that already exists. If you are not ready to commit to a full-time hire, fractional business development gives you a senior BD function part-time while the model is still being proven.
3. Plan for cycles of six to eighteen months
B2B decisions involving pharma, hospitals or CROs commonly run six to eighteen months. Buying groups are large, technical qualification takes time, and budget cycles rarely align with your runway.
Three consequences follow. Pipeline gaps must be fixed two to three quarters before they appear in revenue. Follow-up has to be systematic rather than occasional, because the company that stays in contact through the quiet months is the one that gets the request for proposal when the program restarts. And nurturing needs to be personalized enough that a contact remembers who you are eight months after the first exchange.
4. Build systems that survive growth
Most funded companies run their first commercial year on a spreadsheet. That works until it does not. Once several people touch the same accounts, a CRM configured for long cycles becomes the difference between a forecast and a guess.
Configure it for the reality of the sector: multiple stakeholders per account, stage definitions that reflect technical qualification rather than generic sales stages, and a next step recorded on every open opportunity. If an opportunity has no dated next action, it is not an opportunity.
Data security belongs in the same conversation. In life sciences and health IT, clear protocols and audit trails are increasingly a condition of doing business, not a legal afterthought.
5. Produce evidence your next investor can read
Because first financings have tightened, the companies that raise well next are the ones that can show a commercial system, not just a commercial ambition.
Four artifacts do most of the work: a defined ideal client profile with named target accounts, a pipeline with stages and conversion rates you can defend, a small set of reference conversations or pilots with real organizations, and a repeatable outreach process someone other than the founder can run.
None of these require revenue at scale. They require proof that revenue is a process rather than an accident.
What not to do after a round
Do not hire a VP of Sales as the first commercial move. Between recruitment, onboarding and network building, you are often twelve months and a large salary in before qualified pipeline appears.
Do not hand outbound to a generalist agency. Technical buyers can tell within one exchange whether the sender understands their modality. Generic lead generation language does not survive that test.
Do not measure activity. Emails sent and meetings booked are inputs. A meeting is not pipeline progression and a good conversation is not a qualified opportunity.
Do not enter three markets at once. Sequencing one market properly beats a shallow presence in several.
A twelve month sequence that works
Months 1 to 3. Define the ideal client profile, the buying committee and the disqualifiers. Build the first target account list. Set the two channels you will run.
Months 4 to 6. Run outbound consistently. Instrument the funnel. Establish what a qualified opportunity means in your context, and start measuring conversion at each stage.
Months 7 to 9. Convert early conversations into pilots or references. Fix the stage where opportunities stall. Decide whether the volume justifies a full-time hire.
Months 10 to 12. Hand the process to a permanent owner, with a documented playbook, a working CRM and a pipeline that someone else can run. That handover is the asset, more than any single deal.
Frequently asked questions
What should a life sciences company do first after raising a round?
Define the commercial strategy in parallel with R&D milestones rather than after them. Companies that structure go-to-market early reach their first qualified pipeline months sooner.
How much venture funding went into healthcare and biotech in 2025?
Roughly 71.7 billion dollars globally, the second largest sector after AI, within total venture funding of 425 billion dollars, according to Crunchbase. Biotech first financings, however, fell to 900 million dollars in the second quarter of 2025.
Why do funded life sciences companies stall commercially?
Commercial strategy that starts after the product, hiring driven by urgency rather than by a defined go-to-market, and plans built on quarterly rhythms in a market where decisions take six to eighteen months.
Should a funded biotech hire a VP of Sales or use fractional business development?
A full-time VP of Sales often takes around twelve months and a senior salary before qualified pipeline appears. Fractional business development gives a company a senior BD function part-time while the commercial model is still being proven.
How long are B2B sales cycles in life sciences?
Six to eighteen months with pharma, hospitals or CROs, and complex CRO or CDMO engagements often exceed twelve months. Pipeline gaps therefore have to be fixed two to three quarters ahead.
Turn your round into commercial traction
Corstrate is a PharmD-led business development consultancy that helps life sciences companies build a predictable pipeline in the US and UK markets. If you have raised recently and want the commercial system in place before the next round, get in touch.
Comments